chartexchange

Paysign: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 14, 2026 9:15 PM EST

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Paysign (NASDAQ:PAYS) announced a 43% year-over-year revenue increase to $30.8 million, driven by expansion in its pharmaceutical copay assistance business. The shift from transactional plasma donor card processing toward higher-margin patient affordability solutions is accelerating overall profitability and lifting gross margins. Three things management said stand out. Pharma patient affordability revenue, which provides financial assistance cards for prescription medications, grew 110% year-over-year to $16.6 million as the number of active programs expanded. This higher-margin segment now generates more revenue than legacy payment processing for plasma collection centers. A plasma client is transitioning 113 collection centers to an existing banking partner by year-end, which will reduce fourth-quarter revenue by $1.5 million and gross profit by $700,000. Management expects to offset these losses over subsequent quarters through existing client expansion and new customer acquisition. Continue reading

Read original article